SPY423.11+2.25 0.53%
DIA339.45+0.67 0.20%
IXIC14,253.27+111.79 0.79%

Insider Trends: Athenex Insider Reports Option Conversion in Face of 90-Day Selling Trend

05/07/2021 13:15

05:01 PM EDT, 05/07/2021 (MT Newswires) -- On May 07, 2021, Dr Rudolf Kwan, EVP, Chief Medical Officer, exercised options for 24,000 shares in Athenex (ATNX) for $109,200. Following the Form 4 filing with the SEC, Dr Kwan owns 167,768 shares of the company, with a market value, based on the prior-day closing price, of $718,047.

In the 90 days prior to the date of this filing, there have been 4 insider transactions reported to the SEC for Athenex. These transactions came from the activities of 3 individual insiders that resulted in a net disposition of 507,931 company shares. In the preceding 90-day window of time, there were 3 transactions from 1 insider which resulted in the acquisition of 12,000 shares.

This is lower than the average level of insider transactions in the 324-company Bio Therapeutic Drugs peer group over the last 90-day period. Peer group activity averaged 60.0 transactions per company, with company insiders acquiring on average 36,322 shares.

SEC Story Link http://www.sec.gov/Archives/edgar/data/1300699/000120919121030958/xslF345X03/doc4.xml

This report does not constitute a recommendation to purchase or sell any security and the analysts are not registered investment advisors. Further analysis is recommended before undertaking any position in any security. Any risks are solely the responsibility of the buyer/seller. The authors, publishers and distributors of the MT Newswires Live Briefs service and any associates thereof accept no liability for the content or actions taken by anyone or institution utilizing this report.